WASHINGTON, October 1 — The story begins in a hearing room where the future of federal marijuana policy hung in the balance, only to be halted by a government watchdog’s scathing assessment of the very machinery used to make such decisions. A Drug Enforcement Administration judge paused proceedings on Tuesday after opponents of rescheduling seized on a Government Accountability Office report that exposed fundamental gaps in how federal agencies evaluate controlled substances.
Chief Administrative Law Judge Derek Julius granted a stay requested by the National Drug and Alcohol Association, DUID Victim Voices, and Dr. Kenneth Finn, groups that have argued against moving marijuana from Schedule I to Schedule III.
The report that changed everything
The GAO document, released on September 24, landed like a stone in still water. It concluded that the DEA lacks written policies or procedures for how its staff conduct evaluations or schedule substances. The Food and Drug Administration, the report found, similarly operates without formal procedures for conducting evaluations or developing scheduling recommendations.
For those involved, the implications were immediate. The opponents’ motion argued that the government’s case for rescheduling rests on an evaluation that is “only as good as the process that produced it.” Without written criteria, they contended, the findings required to justify moving marijuana to Schedule III lack a verifiable foundation.
A hearing already months in the making
What unfolded over June and July was a formal hearing initiated under an order signed by Attorney General Todd Blanche in April. The directive instructed the agency to consider a comprehensive reclassification, building on an earlier order that had already moved state-licensed medical cannabis and FDA-approved marijuana products to Schedule III. Testimony had been taken.
The DEA’s recommendation — the expected next step — was pending. Now the record is frozen.
What comes next
Judge Julius ordered the DEA to file a response of up to twenty pages by October 13 addressing whether the hearing record should be reopened to include the GAO report. Other parties may file responses under the same limits, though they are not required to do so. Until the judge rules on that motion, the stay holds.
At its heart, this pause is about process as much as policy. The agencies tasked with scheduling the nation’s controlled substances have been operating without documented standards for how they reach their conclusions.
The GAO has now put that absence in writing. The question before the court, and ultimately the administration, is whether a decision of this magnitude can proceed on a foundation the government’s own auditors say does not exist.
